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Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers due to its 24 
aggressive and metastatic nature. PDA is characterized by a rich tumor stroma with 25 
abundant macrophages, fibroblasts and collagen deposition that can represent up to 26 
90% of the tumor mass. Activation of the tyrosine kinase receptor AXL and expression 27 
of its ligand growth arrest-specific protein 6 (Gas6) correlate with a poor prognosis and 28 
increased metastasis in pancreatic cancer patients. Gas6 is a multifunctional protein 29 
that can be secreted by several cell types and regulates multiple processes, including 30 
cancer cell plasticity, angiogenesis and immune cell functions. However, the role of 31 
Gas6 in pancreatic cancer metastasis has not been fully investigated. In these studies 32 
we find that, in pancreatic tumors, Gas6 is mainly produced by tumor associated 33 
macrophages (TAMs) and cancer associated fibroblasts (CAFs) and that 34 
pharmacological blockade of Gas6 signaling partially reverses epithelial-to-35 
mesenchymal transition (EMT) of tumor cells and supports NK cell activation, thereby 36 
inhibiting pancreatic cancer metastasis. Our data suggest that Gas6 simultaneously 37 
acts on both the tumor cells and the NK cells to support pancreatic cancer metastasis. 38 
This study supports the rationale for targeting Gas6 in pancreatic cancer and use NK 39 









Introduction  47 
Growth arrest-specific gene 6 (Gas6) is a multifunctional factor that regulates several 48 
processes in normal physiology and pathophysiology 35.Gas6 binds to the Tyro3, Axl 49 
and Mer (TAM) family of receptor tyrosine kinases (TAM receptors) with the highest 50 
affinity for Axl 41. Gas6 supports erythropoiesis, platelet aggregation, angiogenesis, 51 
efferocytosis, and inhibits the immune response 24. Gas6 is critical for the maintenance 52 
of immune homeostasis and mice deficient in Gas6 or TAM receptors experience 53 
severe autoimmune diseases 27. Gas6 and its main receptor Axl are overexpressed in 54 
several cancer types including, breast, ovarian, gastric, glioblastoma, lung and 55 
pancreatic cancer and their expression correlates with a poor prognosis 51. Axl is 56 
ubiquitously expressed in all tissues 13 but is particularly notable in cancer cells, 57 
macrophages, dendritic cells and natural killer cells for its role in driving 58 
immunosuppression and tumor progression 12, 30, 34. Several cancer studies have 59 
focused on the role of Gas6-Axl signaling on the tumor cells and have demonstrated 60 
that Axl activation supports tumor cells proliferation, epithelial-mesenchymal transition 61 
(EMT), drug resistance, migration and metastasis 51. Factors secreted within the tumor 62 
microenvironment are able to sustain Gas6/Axl signaling. Hypoxia Inducible Factor 63 
(HIF) has been shown to bind to the Axl promoter region and upregulate its expression 64 
on renal cell carcinoma cells 38. Secretion of IL-10 and M-CSF by tumor cells induces 65 
tumor associated macrophages to secrete Gas6 25. 66 
However, only a few studies have investigated the role of Gas6-Axl signaling in the 67 
immune response to breast cancer, ovarian cancer and melanoma 12, 34. 68 
In solid tumors such as breast or pancreatic cancer, the tumor stroma can represent 69 
up to 80% of the tumor mass and actively influences cancer progression, metastasis 70 
16, 31, 37 and resistance to therapies 4, 15, 43.  71 
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Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal cancers worldwide 72 
and better therapies are urgently needed 44. Metastasis, therapy resistance, and 73 
immunosuppression are key characteristics of pancreatic tumors 18, 52. The Gas6–Axl 74 
pathway is activated in 70% of pancreatic cancer patients 45 and is associated with a 75 
poor prognosis and increased frequency of distant metastasis 21. Blocking Gas6-Axl 76 
signaling inhibits cancer progression 20, 28 and several Axl inhibitors and warfarin (a 77 
vitamin K antagonist that blocks Gas6 signaling) are currently being tested in cancer 78 
patients, including PDA patients. While the cancer cell autonomous functions of Gas6 79 
are well documented, the effect of Gas6 signaling in the stroma/immune compartment 80 
in pancreatic cancer has not been fully explored. In these studies, we sought to 81 
understand the effect of Gas6 blockade in both the tumor and the stroma/immune 82 
compartments, in vivo, in pancreatic cancer.  Gaining a better understanding of how 83 
blockade of Gas6 signaling affects pancreatic cancer is important because it will help 84 
design and interpret the results of the recently launched clinical trials that are testing 85 
anti-Gas6/TAM receptors therapies in pancreatic cancer patients 9. 86 
Results 87 
Pharmacological blockade of Gas6 inhibits spontaneous pancreatic cancer 88 
metastasis.  89 
To investigate the effect of Gas6 blockade in pancreatic cancer growth and 90 
metastasis, we used an orthotopic syngeneic pancreatic cancer model, in which 91 
pancreatic cancer cells derived from the gold standard genetic mouse model of 92 
pancreatic cancer (LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre mice; KPC model), transduced 93 
with a reporter lentivirus expressing zsGreen/luciferase, were orthotopically implanted 94 
into the pancreas of syngeneic immuno-competent mice. This model faithfully 95 
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recapitulates features of the human disease, and tumors are highly infiltrated by 96 
macrophages and are rich in fibroblasts 15, 36, 53. Importantly, pancreatic tumors from 97 
this mouse model also showed expression and activation of Axl receptor 98 
(Supplementary Figure 1A). These mice were then treated with isotype control IgG 99 
antibody or an anti-Gas6 neutralizing antibody (Figure 1A). This anti-Gas6 neutralizing 100 
antibody has previously been shown to block Gas6 signaling through the AXL receptor 101 
to a similar extent as an anti-AXL antibody 47. 30 days after implantation, pancreatic 102 
tumors, lungs, livers and mesenteric lymph nodes were surgically removed and 103 
analysed.  As expected, control treated mice showed high levels of Axl receptor 104 
activation in tumors, whereas the anti-Gas6 treated group showed markedly reduced 105 
levels of Axl receptor activation, confirming that anti-Gas6 antibody has reached the 106 
tumor and has blocked Axl signaling (Supplementary Figure 1A).  No differences were 107 
seen in primary pancreatic tumor growth (Figure 1B) between the control and anti-108 
Gas6 treatment groups. However, mice treated with the anti-Gas6 antibody showed 109 
reduced metastasis to lungs, livers and mesenteric lymph nodes, compared to control 110 
treated mice, as assessed by biolumiscence ex-vivo imaging of these organs 111 
(Supplementary Figure 1C and D). Since lungs showed the highest level of metastasis 112 
in this model, lung tissues were further assessed for metastasis by H&E and 113 
cytokeratin 19 (CK19) staining. We observed that both the number of metastatic foci, 114 
as well as the size of the metastatic lesions were significantly reduced in control versus 115 
anti-Gas6 treated mice (Figure 1D and E, supplementary Figure 1E, F and G). As a 116 
consequence the overall metastatic burden was very significantly reduced in the mice 117 
treated with anti-Gas6 blocking antibody compared to control mice (Figure 1F). These 118 
data suggest that blockade of Gas6 affects the metastatic cascade at different stages, 119 
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affecting the metastatic spreading and/or initial seeding as well as the metastatic 120 
outgrowth of disseminated pancreatic cancer cells. 121 
 122 
Tumor associated macrophages and fibroblasts are the main sources of Gas6 123 
in pancreatic cancer. 124 
Gas6 is a multifunctional protein that is secreted by different cell types. Gas6 has been 125 
shown to be produced by macrophages in pre-malignant lesions of a mammary tumor 126 
model 11 and in xenograft and orthotopic models of colon and pancreatic cancer 26. 127 
Gas6 can also be produced by tumor cells 2 and fibroblasts 8. To determine which cell 128 
types produce Gas6 in pancreatic tumors, tumors were harvested at day 23, and tumor 129 
cells (CD45-/zsGreen+), non-immune stromal cells (CD45-/zsGreen-), M1-like 130 
macrophages (CD45+/F4/80+/CD206-) and M2-like macrophages 131 
(CD45+/F4/80+/CD206+) were isolated by flow cytometry (Figure 2A and 132 
supplementary Figure 2A) and analyzed for the expression of gas6 (Figure 2A, B). We 133 
found that both F4/80+/CD206+ (M2-like macrophages) and SMA+ stromal cells 134 
(Supplementary Figure 2B) are the main sources of gas6 in pancreatic tumors (Figure 135 
2B). Ex-vivo, bone-marrow derived macrophages and pancreatic fibroblasts also 136 
produce Gas6 (Figure 2B, C). In agreement with these findings, we observed that 137 
tumor areas with activated Axl receptor were often surrounded by TAMs and CAFs 138 
(Figure 2D). Analysis of Axl expression and activation in pancreatic cancer patient 139 
samples has been correlated with a poor prognosis 21, 45 and Axl activation in cancer 140 
cells has been shown to support EMT, cell proliferation, metastasis and drug 141 
resistance 51. While these studies have mainly focused on analyzing the expression 142 
and function of Axl on the cancer cells, Axl is also expressed in immune cells, 143 
endothelial cells and stromal cells and regulates innate immunity 24, 27, angiogenesis 144 
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22, 29, 32 and fibrosis 8. In agreement with this multi-functional role for Axl, we found that 145 
Axl is activated in both the tumor and the stromal/immune compartment in biopsies 146 
from pancreatic cancer patients (Figure 3A, B).  147 
 148 
Gas6 blockade alters EMT of pancreatic cancer cells but does not affect 149 
angiogenesis or collagen deposition in pancreatic tumors. 150 
Previous studies have shown that Gas6-Axl signaling promotes tumor cells’ EMT 1, 50. 151 
To determine whether the reduced metastasis observed when we block Gas6 was 152 
caused by an effect on tumor cell EMT we evaluated the expression of EMT markers 153 
and transcription factors on tumor cells from pancreatic tumors treated with isotype 154 
control antibody or Gas6 blocking antibody. Tumor cells isolated from pancreatic 155 
tumors were analysed for the expression of the EMT transcription factors Snail 1, Snail 156 
2, Twist 1, Twist 2, Zeb 1 and Zeb 2 (Figure 4A), the epithelial markers E-cadherin, b-157 
catenin and Epcam and the mesenchymal markers Vimentin and N-cadherin (Figure 158 
4B). We found that blocking of Gas6 significantly decreased the expression of the EMT 159 
transcription factors Snail 1, Snail 2 and Zeb 2, while twist 1 and Zeb 1 levels remained 160 
unchanged and twist 2 was not expressed in pancreatic cancer cells (Figure 4A). In 161 
agreement with this observation, Gas6 blockade also decreased the expression of the 162 
mesenchymal marker Vimentin, while N-cadherin levels were very low and remained 163 
unchanged. E-cadherin and -catenin levels were also decreased though upon anti-164 
Gas6 treatment, suggesting that Gas6 signaling partially regulates cancer cell 165 
plasticity, a phenomenon previously described in cancer 5, 40. Kirane et al. previously 166 
showed that blocking Gas6 signaling with warfarin decreases vimentin expression in 167 
a xenograft model of pancreatic cancer 20. 168 
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To further investigate the effect of anti-Gas6 on vimentin expression in pancreatic 169 
cancer cells in our in vivo tumor model, we analysed vimentin protein expression in 170 
pancreatic tumor tissues from control and anti-Gas6 treated mice (Figure 4C, D). We 171 
found that blockade of Gas6 partially reduces vimentin protein expression in cancer 172 
cells, although this decrease was not statistically significant.  173 
Pancreatic tumors are usually poorly vascularized but since Gas6 signaling can 174 
support endothelial cells proliferation and vascularization 19, 29, 54 we next evaluated 175 
whether anti-Gas6 therapy could affect angiogenesis in pancreatic tumors. Pancreatic 176 
tumor tissues from control and anti-Gas6 treated mice were stained with the 177 
endothelial marker CD31, whole tumor tissues were scanned and quantified for CD31 178 
expression which remained unchanged in both treatment groups (Supplementary 179 
Figure 3A, B). Fourcot et al., showed, in a liver fibrosis model, that Gas6 is secreted 180 
by macrophages and fibroblasts and that Gas6 deficiency decreases TGFb and 181 
collagen I production by hepatic fibroblasts 8. Gas6 also stimulates the proliferation of 182 
cardiac fibroblasts 46. Since fibrosis and collagen deposition have been suggested to 183 
re-strain the metastatic spreading of pancreatic cancer cells 23, 33, 39, 49, we next 184 
investigated whether Gas6 blockade could affect fibroblasts and collagen deposition 185 
in pancreatic tumors. Pancreatic tumor tissues from control and anti-Gas6 treated 186 
mice were stained with picrosirius red to assess collagen deposition (Supplementary 187 
Figure 3C, D) and for SMA+ cells (Supplementary Figure 3 E, F). Whole tumor 188 
tissues were scanned and quantified for collagen deposition (Sirius red positive areas) 189 
and SMA+ cells. We observed a slight increase in collagen deposition in tumors from 190 
mice treated with anti-Gas6 antibody compared to control but this increase was not 191 
statistically significant (Supplementary Figure 3C, D). SMA levels remained the same 192 
in both treatment groups (Supplementary Figure 3 E, F). These findings suggest that 193 
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the anti-metastatic effect of Gas6 blockade in pancreatic cancer is not due to changes 194 
in angiogenesis or fibrosis. 195 
 196 
Gas6 blockade does not affect myeloid cells or T cells populations at the primary 197 
tumour site, in peripheral blood or at the metastatic site. 198 
TAM receptors are also expressed by immune cells and regulate myeloid cell and T-199 
cell functions 3, 24. Thus, next, with the aim to understand the systemic effect of Gas6 200 
blockade in myeloid cells and T cells in pancreatic cancer, we evaluated the number 201 
and activation status of myeloid cells and T cells in pancreatic tumors, blood and 202 
metastatic tissues using mass and flow cytometry.  Mass cytometry analysis of 203 
myeloid (CD11b+) cells, neutrophils/MDSCs (CD11b+/Ly6G+), monocytes 204 
(CD11b+/Ly6C+), macrophages (CD11b+/F4/80+), MHC-II+, CD206+ and PD-L1+ 205 
macrophages (Figure 5A) and T cells (CD3+), helper T-cells (CD3+/ CD4+),  206 
regulatory T cells (CD3+/CD4+/CD25+), cytotoxic T cells (CD3+/CD8+), 207 
activated/exhausted cytotoxic T cells (CD8+/CD69+; CD8+/PD-1+) (Figure 5B)  from 208 
pancreatic tumors from control versus anti-Gas6 treated mice did not show any 209 
significant differences (Figure 5A, B and Supplementary Figure 4 A, B). Similarly, 210 
myeloid cell and T cell numbers in blood (Supplementary Figure 5A, B) and metastatic 211 
lungs from mice treated with control or anti-Gas6 antibody remained the same 212 
(Supplementary Figure 6A, B).  213 
 214 
 Gas6 blockade restores NK cell activation and infiltration in metastatic lesions 215 
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TAM signaling is involved in the development of natural killer (NK) cells 48. In an 216 
elegant study, Paolino et al., demonstrated that TAM receptor inhibition activates NK 217 
cells cytotoxic function and thereby decreases metastasis in mouse models of breast 218 
cancer and melanoma 34. Thus, we next hypothesized that the anti-metastatic effect 219 
of Gas6 blockade we observe in our pancreatic cancer model could be due to a re-220 
activation of NK cells. To test this hypothesis we evaluated NK cells in primary 221 
pancreatic tumors, tumor draining lymph nodes, and metastatic lesions of mice treated 222 
with control IgG or anti-Gas6 antibody. NK cells were almost absent in all primary 223 
tumors from both anti-Gas6 and control treated mice (except for one anti-Gas6 treated 224 
pancreatic tumor). (Supplementary Figure 7). However, the number of NKp46+ NK 225 
cells in lung metastatic lesions was significantly higher in mice treated with anti-Gas6 226 
antibody compared to control treated mice (Figure 6 A, B). The number of NK cells, 227 
and in particular the number of proliferating NK cells, was also increased in tumor 228 
draining lymph nodes from anti-Gas6 treated mice compared to control treated mice 229 
(Figure 6 C, D).  230 
To further investigate the effect of inhibiting Gas6-Axl signaling in pancreatic cancer 231 
progression and metastasis, we performed another in vivo experiment, using our 232 
syngeneic orthotopic KPC model (described in Figure 1) using warfarin (instead of a 233 
neutralising anti-Gas6 antibody). Warfarin is a vitamin K antagonist that inhibits the 234 
vitamin k dependent γ-carboxylation of Gas6 and prevents it from activating TAM 235 
receptors 10, 20. Warfarin is currently being tested in pancreatic cancer patients 236 
(NCT03536208). Similar to what we observed with the anti-Gas6 treatment, warfarin 237 
reduced pancreatic cancer metastasis to the lungs (Figure 7 C, D and Supplementary 238 
Figure 8 B-C) and increased the number and activation of NK cells in lungs (Figure 239 
7E, F) and mesenteric lymph nodes (Figure 7 G, H), as shown by the increase in 240 
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NKp46+ and granzyme B expression. Warfarin treatment also decreased vimentin 241 
expression in pancreatic cancer cells, suggesting that warfarin also acts on the cancer 242 
cells altering their plasticity (Supplementary figure 8D, E). 243 
Discussion 244 
The data presented in this study describe a dual anti-tumor effect of Gas6 blockade in 245 
pancreatic tumors, shedding light on the anti-cancer mechanism of action of inhibitors 246 
of the Gas6-Axl pathway and supporting the rationale for using anti-Gas6 therapy in 247 
pancreatic cancer patients. In these studies we show that blockade of Gas6 in 248 
pancreatic tumors, with either an anti-Gas6 neutralising antibody or with warfarin, acts 249 
simultaneously on both the tumor cells, altering their epithelial-mesenchymal 250 
phenotype, as well as on NK cells, promoting their activation and recruitment to the 251 
metastatic site (Figure 6 and 7). These findings suggest that anti-Gas6 therapy 252 
decreases pancreatic cancer metastasis by not only affecting cancer cells’ plasticity 253 
but also by activating NK cells and supporting their tumoricidal function.  254 
So far many studies have focused on the cancer-cell autonomous role of Gas6 and 255 
based on their effect on tumor cell proliferation and plasticity several inhibitors of the 256 
Gas6-Axl pathways, including warfarin (clinical trial ID: NCT03536208) are currently 257 
being tested in pancreatic cancer patients.   258 
Our studies show that inhibition of Gas6 signaling in pancreatic cancer not only affects 259 
the tumor cells but notably affects the NK cells. Our findings suggest that the activation 260 
status of NK cells should also be assessed in cancer patients and could be used as a 261 
biomarker to monitor response to anti-Gas6/Axl therapies.  262 
Gas6/Axl signaling is a negative regulator of the immune system and inhibition of the 263 
Gas6-Axl signaling leads to autoimmunity 27. While the function of Gas6-Axl signaling 264 
on tumor cell proliferation, EMT, migration and drug resistance has been extensively 265 
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studied 51, only a few studies have investigated the role of Gas6/Axl signaling in the 266 
immune system in the context of cancer 12, 28, 34. Guo et al., found that the Axl inhibitor 267 
R428 inhibited tumor growth of subcutaneously implanted murine 4T1 breast cancer 268 
cells and intra-peritoneally implanted murine ID8 ovarian cancer cells by activating 269 
CD4+ and CD8+ T cells 12. Inspired by this study, we investigated whether, in our 270 
pancreatic cancer model, Gas6 blockade supports the activation of T cells. Unlike Guo 271 
et al., we did not observe any statistically significant difference in CD4+ or CD8+ T 272 
cells in pancreatic tumors, blood or metastatic tissues, in control versus anti-Gas6 273 
treated mice. Ludwig et al., found that treating mouse pancreatic tumors with the Axl 274 
inhibitor BGB324 decreased the number of tumor associated macrophages (TAMs) in 275 
some but not all tumor models 28. In our study, blocking Gas6 did not significantly affect 276 
TAMs, other myeloid cell populations or T cells in primary tumors, blood or metastatic 277 
organs. These different results observed in these studies may be explained by the 278 
differences in the tumor models used (breast cancer versus pancreatic cancer; 279 
xenograft versus syngeneic models) and the differences in the therapies used 280 
(inhibition of AXL receptor versus inhibition of Gas6 ligand which binds all TAM 281 
receptors).  In another study, Paolino et al., showed that TAM receptor inhibition 282 
activates NK cells in mouse tumor models of melanoma and breast cancer leading to 283 
decreased tumor growth 34. In agreement with these findings, we found that blocking 284 
Gas6 in mice bearing pancreatic tumors, increases NK cell number and activation in 285 
tumor draining lymph nodes and lungs, and decreases pancreatic cancer metastasis.  286 
Inhibition of the Gas6-Axl pathway has been shown to reverse EMT, tumor migration 287 
and intra-tumoral micro-vessel density in pancreatic cancer 20. In agreement with these 288 
findings, we found that inhibition of Gas6 signaling decreases the expression of the 289 
EMT transcription factors snail 1, snail 2, Zeb2 and vimentin expression in pancreatic 290 
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cancer cells. E-cadherin and b-catenin levels were also decreased upon anti-Gas6 291 
treatment suggesting that blockade of Gas6 signaling leads to a partial MET or hybrid 292 
E/M phenotype. Partial EMT is a phenomenon often observed in cancer, where cancer 293 
cells that originate from epithelial cells exhibit both mesenchymal and epithelial 294 
characteristics. The ability of cancer cells to undergo partial EMT, rather than complete 295 
EMT and to maintain the expression of both E-cadherin and vimentin poses a higher 296 
metastatic risk 5, 39. Pancreatic tumors are usually hypo-vascularized compared to a 297 
normal pancreas and anti-angiogenic therapies have not been successful in 298 
pancreatic cancer 6. Similar to the human disease, in our pancreatic mouse tumor 299 
model, tumors are poorly vascularized and blocking Gas6 did not show any further 300 
decrease in tumor vascularization.  Loges et al., previously showed that tumor 301 
associated macrophages (TAMs) produce Gas6 in various mouse tumor models 25. In 302 
our study we found that both TAMs and CAFs are the main sources of Gas6 in 303 
pancreatic tumors.  These findings suggest that the abundance of TAMs and CAFs in 304 
pancreatic cancer patients could be used to determine which patients would benefit 305 
the most from anti-Gas6 therapy. 306 
In conclusion, our studies suggest that in pancreatic cancer, Gas6 is secreted by both 307 
TAMs and CAFs and blockade of Gas6 signaling has a dual anti-metastatic effect by 308 
acting on both the tumor cells and the NK cells. Thus, inactivation of Gas6 signaling 309 
can promote anti-tumor immunity, via NK cell activation, in pancreatic tumors. Since 310 
this Gas6-dependent immune regulation of NK cells is also conserved in humans, anti-311 
Gas6-Axl therapies are likely to promote anti-tumor immunity, via NK cell activation, in 312 
pancreatic cancer patients. This study provides further mechanistic insights into the 313 
mode of action of anti-Gas6 therapies and suggests the use of NK cells as an 314 




Materials and Methods  317 
Generation of primary KPC-derived pancreatic cancer cells 318 
The murine pancreatic cancer cells KPC FC1242 were generated in the Tuveson lab 319 
(Cold Spring Harbor Laboratory, New York, USA) isolated from pancreatic ductal 320 
adenocarcinoma (PDA)  tumor tissues obtained from LSL-KrasG12D; LSL-Trp53R172H; 321 
Pdx1-Cre mice of a pure C57BL/6 background as described previously with minor 322 
modifications 14. 323 
Generation of primary macrophages, primary pancreatic fibroblasts, 324 
macrophage (MCM) and fibroblasts (FCM) conditioned media  325 
Primary murine macrophages were generated by flushing the bone marrow from the 326 
femur and tibia of 6-8 week-old C57BL/6 mice followed by incubation for 5 days in 327 
DMEM containing 10% FBS and 10 ng/mL murine M-CSF (Peprotech). Primary 328 
pancreatic stellate cells were isolated from the pancreas of C57BL/6 mice by density 329 
gradient centrifugation, and were cultured on uncoated plastic dishes in IMDM with 330 
10% FBS and 4mM L-glutamine. Under these culture conditions pancreatic stellate 331 
cells activated into myofibroblasts. 332 
To generate macrophage and fibroblast conditioned media, cells were cultured in 333 
serum free media for 24-36 h, supernatant was harvested, filtered with 0.45µm filter, 334 
concentrated using StrataClean Resin (Agilent Technologies) and immunoblotted for 335 




FC1242 cells were plated in DMEM media with 10% FBS for 24hrs, harvested and 338 
lysed in RIPA buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.2, 0.1% SDS, 1% Triton X-339 
100, 5 mM EDTA) supplemented with a complete protease inhibitor mixture (SIGMA), 340 
a phosphatase inhibitor cocktail (Invitrogen), 1 mM PMSF and 0.2 mM 341 
Na3VO4.Immunoblotting analyses was performed using phospho-Axl antibody (R&D 342 
systems, AF2228). 343 
Syngeneic Orthotopic pancreatic cancer model  344 
1 X 106 primary KPCluc/zsGreen cells (FC1242luc/zsGreen) isolated from a pure C57Bl/6 345 
background were implanted into the pancreas of immune-competent syngeneic 346 
C57Bl/6 six- to eight-week-old female mice, and tumors were established for two 347 
weeks before beginning treatment. Mice were administered i.p. with Gas6 neutralizing 348 
antibody (R&D systems, AB885) (2 mg/kg), or IgG isotype control antibody, every 3 -349 
4 days or warfarin sodium in drinking water (0.5mg/L) which was replenished every 3-350 
4 days, for 15 days before harvest. 351 
Analysis and quantification of immune cells in pancreatic tumors by mass 352 
cytometry  353 
Pancreatic tumors were resected from the mice and mechanically and enzymatically 354 
digested in Hanks Balanced Salt Solution (HBSS) with 1 mg/mL Collagenase P 355 
(Roche) Cell  suspensions  were  centrifuged  for  5  min  at  1500  rpm,  resuspended  356 
in  HBSS and filtered  through  a  500 μm  polypropylene  mesh  (Spectrum  357 
Laboratories).  Cells were resuspended in 1 mL 0.05%Trypsin and incubated at 37oC 358 
for 5 minutes. Cells were filtered through a 70 μm cell strainer and resuspended in 359 
Maxpar cell staining buffer (Fluidigm). The samples were centrifuged for 5 min at 450 360 
x g and supernatant removed. The cells were subsequently stained with Cell-ID 195-361 
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Cisplatin (Fluidigm)  viability marker diluted 1:40 in Maxpar PBS (Fluidigm) for 5 min. 362 
Cells were centrifuged at 450 x g for  5 min and washed twice in Maxpar cell staining 363 
buffer. Samples were blocked for 10 minutes on ice with 1:100 diluted FC Block (BD 364 
Pharmingen, Clone 2.4G2) and metal-conjugated antibody cocktail added and 365 
incubated for 30 min at 4oC. Antibodies were used at the concentrations 366 
recommended by manufacturers. Cells were washed twice in cell staining buffer and 367 
stained with 125 µM 191-Intercalator-Ir (Fluidigm) diluted in 1:2000 Maxpar fix and 368 
perm buffer (Fluidigm) overnight at 4 oC. The cells were washed twice in Maxpar cell 369 
staining buffer and centrifuged at 800 x g for 5 min. A post-fix was performed by 370 
incubating the cells in 1.6% PFA for 30 min at RT. Cells were washed twice in 18Ω 371 
distilled water (Fluidigm), mixed 1:10 with EQTM Four Element Calibration Beads 372 
(Fluidigm) and acquired on the Helios CyTOF system (Fluidigm). Samples were 373 
acquired at a rate of around 200 cells/s. All generated FCS files were normalized and 374 
beads removed 7. All analysis was performed in Cytobank: Manual gating was used 375 
to remove dead cells (195Pt+) and debris and to identify single cells (191 Ir+).  376 
viSNE analysis was performed on the data utilising t-stochastic neighbour embedding 377 
(t-SNE) mapping based on high dimensional relationships. CD45+ population selected 378 
by manual gating was used as the starting cell population and using proportional 379 
sampling viSNE unsupervised clustering was performed. Manual gating was then 380 
performed on the viSNE map created to determine cell population percentages. 381 
Spanning-tree Progression Analysis of Density-normalized Events (SPADE) analysis 382 
was performed in Cytobank using manually gated CD45+ cells, 200 target number of 383 
nodes and 10% down sampled events, to equalize the density in different parts of the 384 
cloud. In Cytobank SPADE analysis edge number between nodes indicates levels of 385 
similarity, with more steps indicating less similarity across channels used to create the 386 
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tree. Node localization and edge length cannot be used to infer similarity in this 387 
analysis. Event number is indicated by both colour scale and node size (which is 388 
proportional to the number of cells present in each cluster). Gating of cell populations 389 
was performed to identify major cell populations and percentages.  390 
FACS sorting and analysis of blood and lungs by flow cytometry  391 
Single cell suspensions from murine primary pancreatic tumors and pulmonary 392 
metastasis were prepared by mechanical and enzymatic disruption and tumor cells, 393 
tumor associated macrophages and stromal cells were analysed and sorted using flow 394 
cytometry (FACS ARIA II, BD Bioscience). Samples were digested as outlined above, 395 
the cells were then filtered through a 70 μm cell strainer and resuspended in PBS + 396 
1% BSA, blocked for 10 minutes on ice with FC Block (BD Pharmingen, Clone 2.4G2) 397 
and stained with Sytox® blue viability marker (Life Technologies) and conjugated 398 
antibodies anti-CD45-PE/Cy7 (Biolegend, clone 30-F11) and anti-F4/80-APC  399 
(Biolegend, clone  BM8).  400 
Blood was collected from mice via tail vein bleed in EDTA-tubes. Red blood cell lysis 401 
was performed and resulting leukocytes were resuspended in PBS + 1% BSA and 402 
blocked for 10 mins on ice with FC block and stained with Sytox® blue  viability  marker 403 
and conjugated antibodies anti-CD45-APC/Cy7 (Biolegend, 103115), anti-CD11b-404 
APC (Biolegend, 101212), anti-Ly6G-PerCP-Cy5.5 (Biolegend, 127616), anti-Ly6C-405 
PE (Biolegend, 128008), anti-CD3-PE-Cy7 (Biolegend, 100320), anti-CD4-PE 406 
(Biolegend, 100408) and anti-CD8-PerCP-Cy5.5 (Biolegend, 100734). Cell analysis 407 
was performed using FACS Canto II. 408 
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Gene expression  409 
Total RNA was isolated from FACS sorted tumor cells, tumor associated macrophages 410 
and non-immune stromal cells from primary pancreatic tumors as described in Qiagen 411 
Rneasy protocol.  Total RNA from the different cell populations was extracted using a 412 
high salt lysis buffer (Guanidine thiocynate 5 M, sodium citrate 2.5 uM, lauryl sarcosine 413 
0.5% in H2O) to improve RNA quality followed by purification using Qiagen Rneasy 414 
protocol. cDNA was prepared from 1μg RNA/sample, and qPCR was performed using 415 
gene specific QuantiTect Primer Assay primers from Qiagen. Relative expression 416 
levels were normalized to gapdh expression according to the formula <2^− (Ct gene 417 
of interest – Ct gapdh) 42  418 
 Quantification of metastasis 419 
By IVIS imaging 420 
IVIS spectral imaging of bioluminescence was used for orthotopically implanted tumor 421 
cells expressing firefly luciferase using IVIS spectrum system (Caliper Life Sciences). 422 
Organs were resected for ex vivo imaging coated in 100 µL D-luciferin (Perkin Elmer) 423 
for 1 min and imaged for 2 min at automated optimal exposure.  Analysis was 424 
performed on the Living Image software (PerkinElmer) to calculate the relative 425 
bioluminescence signal from photon per second mode normalised to imaging area 426 
(total flux) as recommended by the manufacturer.   427 
By H&E staining 428 
FFPE lungs were serially sectioned through the entire lung using microtome at 4 µm 429 
thickness. Sections were stained with H&E and images were taken using a Zeiss 430 
Observer Z1 Microscope (Zeiss) to identify metastatic foci. The number of foci were 431 
counted, and the total area of metastatic foci was measured using Zen imaging 432 
software. Metastatic burden was calculated by the following equations: 433 
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No. of foci per 100 mm2: (Average no. foci per section/ average tissue area per section 434 
(mm2) *100 435 
Average metastatic lesion size (mm2): Average total area of metastasis (mm2)/ 436 
average number of foci per section 437 
Total metastatic burden: Sum of area of each foci of each section 438 
By CK19 staining  439 
FFPE Lung tissue sections were also stained for cytokeratin 19 (CK19). The slides 440 
were scanned with an Aperio slide scanner and the whole lung tissue was quantified 441 
for CK19 expression using Image J. 442 
 443 
Immunohistochemistry and Immunofluorescence  444 
Deparaffinization and antigen retrieval was performed using an automated DAKO PT-445 
link. Paraffin-embedded pancreatic tumors, lymph nodes and lung metastasis tissues 446 
were immuno-stained using the DAKO envision+ system-HRP.  447 
Antibodies and procedure used for Immunohistochemistry:  448 
All primary antibodies were incubated for 2 hours at room temperature: αSMA (Abcam, 449 
ab5694 used at 1:200 after low pH antigen retrieval), CD31 (Cell signalling technology, 450 
CST 77699 used at 1:100 after low pH antigen retrieval), NKp46 (Biorbyt, orb13333 451 
used at 1:200) and AF2225 (used at 1:50 after low pH antigen retrieval), CK19 452 
(ab53119 used at 1:100 after low pH antigen retrieval) and CD68 (Abcam, ab31630 453 
used at 1:400 after low pH antigen retrieval). Subsequently, samples were incubated 454 
with secondary HRP-conjugated antibody (from DAKO envision kit) for 30 min at room 455 
temperature. All antibodies were prepared in antibody diluent from Dako envision kit. 456 
Staining was developed using diamino-benzidine and counterstained with 457 
hematoxylin.  458 
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Human paraffin-embedded PDA tissue sections were incubated overnight at RT with 459 
the following primary antibodies: phospho-Axl (R&D, AF2228, used 1:500 after high 460 
pH antigen retrieval), CD163 (Abcam, ab74604 pre-diluted after low pH antigen 461 
retrieval), SMA (Abcam, ab5694 used 1:100 after low pH antigen retrieval), 462 
Antibodies and procedure used for Immunofluorescence 463 
After low pH antigen retrieval, lymph node tissue sections derived from mice bearing 464 
pancreatic tumors were incubated overnight at RT with the following primary 465 
antibodies: NKp46 (R&D systems AF2225, used at 1:25), Ki67 (Abcam ab15580, used 466 
at 1:1000), vimentin (Abcam ab92547, used at 1:400) and Granzyme B (ab4059, used 467 
at 1:600). Vimentin expression was quantified on cancer cells located at the edge of 468 
pancreatic tumors. Samples were washed with PBS and incubated with donkey anti-469 
goat 594 (Abcam ab150132) and donkey anti-rabbit 488 (Abcam ab98473) secondary 470 
antibodies respectively, all used at 1:300 and DAPI at 1:600 for 2 hours at RT. Slides 471 
were washed with PBS, final quick wash with distilled water and mounted using DAKO 472 
fluorescent mounting media.  473 
After low pH antigen retrieval, mouse tissue sections derived from paraffin embedded 474 
pancreatic tumors were incubated with vimentin (ab92547, used at 1:400) overnight 475 
at 4c. Goat anti-rabbit 594 (ab150080) secondary was used at 1:300 and DAPI at 476 
1:600 for 2 hours at RT. 477 
Human PDA frozen tissue sections were fixed with cold acetone, permeabilized in 478 
0.1% Triton, blocked in 8% goat serum and incubated overnight at 4°C with anti-479 
phospho-Axl (R&D, AF2228, diluted 1:200)  CK11 (Cell signaling, CST 4545, diluted 480 
1:200), followed by fluorescently labelled secondary antibodies goat anti mouse 488 481 
(Abcam ab98637), goat anti-rabbit 594 (Abcam ab98473) used at 1:300 for 2 hours at 482 
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RT slides were washed with PBS, final quick wash with distilled water and mounted 483 
using DAKO fluorescent mounting media.  484 
Picrosirius Red staining  485 
FFPE PDA tumor sections were deparaffinized in two 5 min xylene washes and 486 
through decreasing alcohol washes of 100%, 75% and 65% each 5 min. The slides 487 
were washed for 5 min in distilled water and incubated in 0.2 % phosphomolybdic acid 488 
for 5 min. After washing in PBS, were stained with 0.1 % Sirius red F3B in saturated 489 
picric acid solution for 90 min. After two rinses in acidified water the slides were stained 490 
with fast green (0.01 %) for 1 min. The sections were rinsed twice in acidified water 491 
were rapidly dehydrated using 3 steps of 100 % ethanol and two xylene incubations 492 
of 30 sec.  493 
Statistical Methods 494 
Statistical significance for in vitro assays and animal studies was assessed using 495 
unpaired two-tailed Student t test and the GraphPad Prism 5 program. All error bars 496 
indicate SD for in vitro studies and SEM for animal studies.  497 
Institutional approvals 498 
All studies involving human tissues were approved by the University of Liverpool and 499 
were considered exempt according to national guidelines. Human pancreatic cancer 500 
samples were obtained from the Liverpool Tissue Bank from patients that consented 501 
to use the surplus material for research purposes. All animal experiments were 502 
performed in accordance with current UK legislation under an approved project licence 503 
(reference number: 403725). Mice were housed under specific pathogen-free 504 
conditions at the Biomedical Science Unit at the University of Liverpool. 505 
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Figure legends 738 
Figure 1. Pharmacological blockade of Gas6 inhibits pancreatic cancer 739 
metastasis.  740 
(A) KPCluc/zsGreen (zsGreen) -derived pancreatic tumor cells (FC1242luc/zsGreen) were 741 
orthotopically implanted into the pancreas of syngeneic C57BL/6 recipient mice, and 742 
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mice were treated, starting at day 14 after tumor implantation, twice a week i.p., with 743 
either isotype control IgG antibody or Gas6 blocking antibody (2mg/kg). Primary 744 
pancreatic tumors, livers, lungs and mesenteric lymph nodes were harvested at day 745 
30. (B) Tumor weights (n= 11 mice for control IgG treatment group; n=12 mice for anti-746 
Gas6 treatment groups). (C) Representative IVIS images of metastatic lungs from 747 
control IgG and anti-Gas6 treated mice. (D) Representative images of H&E staining of 748 
metastatic lungs from control IgG and anti-Gas6 treated mice. Scale bar 50 μm. 749 
 (E) Quantification of number of lung metastatic foci per 100mm2 in mice treated with 750 
control IgG or anti-Gas6 antibody identified by H&E.  * p ≤ 0.05, using unpaired student 751 
T test, error bars represent SEM (n=7). (F) Average size of pulmonary metastatic 752 
lesions in mice treated with control IgG or anti-Gas6 antibody identified by H&E. * p ≤ 753 
0.05, using unpaired student T test, error bars represent SEM (n=7). (G) Quantification 754 
of total metastatic burden in mice treated with control IgG or anti-Gas6 antibody 755 
identified by H&E. ** p ≤ 0.01, using unpaired student T test, error bars represent SEM 756 
(n=7).  757 
 758 
Figure 2. TAMs and CAFs are the main sources of Gas6 in pancreatic tumors 759 
(A) KPCluc/zsGreen (zsGreen) -derived tumor cells (FC1242luc/zsGreen) were orthotopically 760 
implanted into the pancreas of syngeneic recipient (C57/BL6) mice. Tumors were 761 
harvested and digested at day 23 after implantation and tumor cells, non-immune 762 
stromal cells, M1-like and M2-like macrophages were sorted by flow cytometry. Gas6 763 
mRNA levels were quantified in CD45-/zsGreen+ tumor cells, CD45-/zsGreen- non-764 
immune stromal cells, CD45+/F4/80+/CD206- M1-like macrophages and 765 
CD45+/F4/80+/CD206+ M2-like macrophages sorted by flow cytometry from murine 766 
pancreatic tumors. Values shown are the mean and SD (n=3). (B) Quantification of 767 
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Gas6 mRNA expression levels in ex vivo mouse primary isolated macrophages and 768 
pancreatic fibroblasts from naïve mice. Values shown are the mean and SD (n=3).  (C) 769 
Immunoblotting analysis of Gas6 secreted protein present in mouse macrophage 770 
conditioned media (MCM) and pancreatic fibroblast conditioned media (FCM). (D) 771 
Images show phospho-Axl, SMA (fibroblast marker) and CD68 (pan-macrophage 772 
marker) staining in naïve mouse pancreas and in serial sections of mouse PDA 773 
tissues. Scale bar = 50 μm. 774 
Figure 3. AXL receptor is activated in both the tumor and stromal compartment 775 
in biopsies from PDA patients.  776 
 (A) Immunofluorescent staining of human PDA biopsies with CK11 (tumor cell marker, 777 
in green), phospho-Axl receptor (in red), and nuclei (in blue). Scale bar, 50 m. Yellow 778 
arrow indicates presence of phosphorylated Axl in the stromal compartment. White 779 
arrow indicates presence of phosphorylated Axl in the tumor cells. (B)  Serial sections 780 
of biopsies from human PDA samples immunohistochemically stained for phospho-781 
Axl, CD163 (macrophages) and SMA (fibroblasts). Cancer cells are indicated by a 782 
purple asterisk and tumor stroma is indicated by a pink asterisk. Scale bars, 50 m 783 
and 100 m. 784 
 785 
Figure 4. Gas 6 blockade in pancreatic tumors partially affects EMT of tumor 786 
cells  787 
(A) Quantification of the expression levels of the EMT transcription factors: Snail 1, 788 
Snail 2, Twist 1, Twist 2, Zeb 1 and Zeb 2 in tumor cells (zsGreen+) isolated by flow 789 
cytometry from mouse PDA tumors. Values shown are the mean and SD (n=3).  (B) 790 
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Quantification of the expression levels of the epithelial markers: E-cadherin, b-catenin, 791 
EpCAM and the mesenchymal markers vimentin and N-cadherin in tumor cells FACS 792 
sorted from mouse PDA tumors. Values shown are the mean and SD (n=3).  * p ≤ 793 
0.05, using unpaired student T test; ** p ≤ 0.01, using unpaired student T test; *** p ≤ 794 
0.005, using unpaired student T test. (C) Representative immunofluorescent images 795 
of vimentin staining at the periphery of mouse pancreatic tumors treated with control 796 
IgG or anti-Gas6 antibody. The dashed lines highlight the areas quantified in the tumor 797 
tissues. (D) Quantification of vimentin protein expression levels in pancreatic cancer 798 
cells. Data are displayed as mean and SEM and represent 5 images per mouse, with 799 
7 animals per treatment group. n.s. no statistically significant differences, using 800 
unpaired student T test.                                         801 
 802 
Figure 5. Gas6 blockade does not affect the composition or activation status of 803 
myeloid cells and T cells in pancreatic tumours 804 
(A) Mass cytometry quantification of CD11b + myeloid cells, Ly6C high/Ly6C low 805 
monocytes/MDSCs, Ly6G high/Ly6C low neutrophils/MDSCs, F4/80+ macrophages, 806 
MHCII+ macrophages, CD206+ macrophages and PD-L1+ macrophages in mouse 807 
pancreatic tumors treated with control IgG (n=3) or anti-Gas6 neutralizing antibody 808 
(n=4). Values shown are mean and SEM. n.s. no statistically significant differences, 809 
using unpaired student T test. (B) Mass cytometry quantification of CD3+ T cells, 810 
CD4+ T cells, CD4+/CD25+ regulatory T cells (Tregs), CD8+ T cells, CD69+/CD8+ T 811 
cells and PD-1+/CD8+ T cells in mouse pancreatic tumors treated with control IgG 812 
(n=3) or anti-Gas6 neutralizing antibody (n=4). Values shown are mean and SEM. n.s. 813 
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no statistically significant differences, using unpaired student T test.  Graphs were 814 
generated with ViSNE data using Cytobank software. 815 
 816 
Figure 6. Gas6 blockade increases NK cell numbers in metastatic lungs and in 817 
tumor draining lymph nodes. 818 
(A) Immunohistochemical staining of NK cells in metastatic lungs from pancreatic 819 
tumor bearing mice treated with control IgG or anti-Gas6 antibody. Lesions indicated 820 
by dashed line and NK cells by red asterisk. Scale bar, 50 m. (B) Quantification of 821 
NK cells in metastatic lung tissues from control IgG and anti-Gas6 treated mice. 822 
Values shown are the mean and SEM (n=6 mice in IgG treatment group, n=7 mice in 823 
anti-Gas6 treatment group).  ** p ≤ 0.01, using unpaired student T test. (C) 824 
Immunofluorescent staining of NK cells in mesenteric lymph nodes from pancreatic 825 
tumor bearing mice treated with control IgG or anti-Gas6 antibody.  NK marker NKp46 826 
is shown in red, Ki67 is shown in green and nuclei were stained with DAPI (in blue).  827 
Scale bar, 50 m.  (D)  Quantification of NK cells in tumor draining lymph nodes from 828 
control IgG and anti-Gas6 treated mice. Values shown are the mean and SEM (n=6 829 
mice IgG treatment group and n=7 mice anti-Gas6 treatment group, 3-6 fields/ mouse 830 
tissue were quantified).  * p ≤ 0.05, using unpaired student T test.  831 
 832 
 833 
Figure 7. Warfarin decreases pancreatic cancer metastasis and increase NK cell 834 
numbers and activation in lymph nodes and at the metastatic site. 835 
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 (A) KPCluc/zsGreen (zsGreen) -derived pancreatic tumor cells (FC1242luc/zsGreen) were 836 
orthotopically implanted into the pancreas of syngeneic C57BL/6 recipient mice. At 837 
day 14 the mice were treated with either control drinking water or warfarin sodium in 838 
drinking water (0.5mg/L). Warfarin water was replenished every 3-4 days. Primary 839 
tumors, livers, lungs and lymph nodes were harvested at day 29/30. (B) Tumor weights 840 
from control (n=7) or warfarin (n=6) treated mice. (C) Immunohistochemical staining 841 
of CK19+ in mice with lung metastases. (D) Quantification of the total area of lung 842 
metastasis per mouse as a percentage of the total lung area for control (n=4) or 843 
warfarin (n=3) treated mice. * p ≤0.05 using unpaired student T test. Values shown are 844 
mean and SEM. (E) Immunohistochemical staining of NKp46+ NK cells in the lungs 845 
from pancreatic tumor bearing mice. (F) Quantification of the number of NKp46+ NK 846 
cells per cm2 in the lungs of control (n=7) or warfarin (n=6) treated mice. * p <0.05, 847 
using unpaired student T test. 848 
 849 
Figure 8. Schematics depicting the multifunctional role of stroma-derived Gas6 850 
in pancreatic cancer. 851 
In vivo blockade of Gas6 signalling with a neutralising anti-Gas6 antibody or warfarin, 852 
partially reverses tumor cells EMT and activates NK cells, leading to a decrease in 853 
pancreatic cancer metastasis. 854 
